Melatonin and Quality of Life

  • Venkataramanujan Srinivasan
  • S. R. Pandi-Perumal
  • Warren Spence
  • Daniel P. Cardinali
  • Marcel G. Smits

Summary

There is substantial evidence that fragmented sleep, delayed sleep phase syndrome (DSPS), insomnia, and impaired daytime alertness are the result of disorders in brain functioning that are closely linked to disruptions in the regulation of circadian rhythms. In children suffering from neurodevelopmental disabilities, such as attention deficit hyperactivity disorder (ADHD) and epilepsy, sleep disturbance and behavioral problems are significant correlated symptoms. There is also evidence that by addressing these problems directly, significant improvements can be made in the quality of life (QOL) experienced by the affected individuals. Children with ADHD exhibit impairments in the circadian pacemaker as shown by studies confirming an associated delay in the peak melatonin output under dim light conditions. Therapy involving melatonin administration to these children not only improves their sleep onset and efficiency but also improves their health status and QOL. The QOL of young adults who suffer from DSPS is significantly impaired by the resulting symptoms of insomnia and tiredness. Treatment of DSPS patients with melatonin has been reported to improve QOL dimensions such as physical functioning, mental health, and emotional well-being, as well as social functioning and general health. In patients suffering from chronic fatigue syndrome, melatonin improved QOL by enhancing vitality and energy and by reducing pain perception and fatigue. Melatonin has also been demonstrated to improve the quality of sleep of elderly insomniacs. Strategically timed administration of melatonin is useful for reducing the symptoms of jet-lag in intercontinental travelers. Additionally, melatonin has been found to enhance the nighttime alertness of shift workers and to improve their sleep during the daytime. Melatonin has a promising role in cancer patients not only as an oncostatic drug but also in promoting their general physical health and well-being. Meditation, besides improving QOL, coincidentally enhances the secretion of melatonin from the pineal gland, thus suggesting that melatonin may be an important physical mediator of the meditation experience.

Keywords

Melatonin attention deficit hyperactivity disorder chronic fatigue syndrome epilepsy jet-lag shift work quality of life cancer meditation 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Helmer C, Pasquier F, Dartigues JF. Epidemiology of Alzheimer disease and related disorders. Med Sci (Paris) 2006;22(3):288–296.Google Scholar
  2. 2.
    Kivipelto M, Solomon A. Cholesterol as a risk factor for Alzheimer’s disease – epidemiological evidence. Acta Neurol Scand Suppl 2006; 185:50–57.PubMedCrossRefGoogle Scholar
  3. 3.
    Blennow K, de Leon MJ, Zetterberg H. Alzheimer’s disease. Lancet 2006; 368(9533):387–403.PubMedCrossRefGoogle Scholar
  4. 4.
    Rosano C, Newman AB. Cardiovascular disease and risk of Alzheimer’s disease. Neurol Res 2006; 28(6):612–620.PubMedCrossRefGoogle Scholar
  5. 5.
    Reiter RJ, Tan DX, Allegra M. Melatonin: reducing molecular pathology and dysfunction due to free radicals and associated reactants. Neuro Endocrinol Lett 2002; 23 (Suppl 1): 3–8.PubMedGoogle Scholar
  6. 6.
    Cardinali DP, Furio AM, Reyes MP, Brusco LI. The use of chronobiotics in the resynchronization of the sleep-wake cycle. Cancer Causes Control 2006; 17(4):601–609.PubMedCrossRefGoogle Scholar
  7. 7.
    Pandi-Perumal SR, Zisapel N, Srinivasan V, Cardinali DP. Melatonin and sleep in aging population. Exp Gerontol 2005; 40(12):911–925.PubMedCrossRefGoogle Scholar
  8. 8.
    Srinivasan V, Maestroni G, Cardinali D, Esquifino A, Perumal SP, Miller S. Melatonin, immune function and aging. Immun Ageing 2005; 2:17.PubMedCrossRefGoogle Scholar
  9. 9.
    Srinivasan V, Pandi-Perumal SR, Maestroni GJ, Esquifino AI, Hardeland R, Cardinali DP. Role of melatonin in neurodegenerative diseases. Neurotox Res 2005; 7(4):293–318.PubMedCrossRefGoogle Scholar
  10. 10.
    Karasek M. Melatonin, human aging, and age-related diseases. Exp Gerontol 2004; 39(11–12):1723–1729.PubMedCrossRefGoogle Scholar
  11. 11.
    Srinivasan V, Pandi-Perumal S, Cardinali D, Poeggeler B, Hardeland R. Melatonin in Alzheimer’s disease and other neurodegenerative disorders. Behav Brain Funct 2006; 2(1):15.PubMedCrossRefGoogle Scholar
  12. 12.
    Smits MG, Nagtegaal EE, van der HJ, Coenen AM, Kerkhof GA. Melatonin for chronic sleep onset insomnia in children: a randomized placebo-controlled trial. J Child Neurol 2001; 16(2):86–92.PubMedCrossRefGoogle Scholar
  13. 13.
    Smits MG, Rooy RV, Nagtegaal JE. Influence of melatonin on quality of life in patients with chronic fatigue and late melatonin onset. J Chronic Fatigue Syndr 2002; 10:25–36.CrossRefGoogle Scholar
  14. 14.
    Smits MG, van Stel HF, van der HK, Meijer AM, Coenen AM, Kerkhof GA. Melatonin improves health status and sleep in children with idiopathic chronic sleep-onset insomnia: a randomized placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2003; 42(11):1286–1293.PubMedCrossRefGoogle Scholar
  15. 15.
    Gupta M, Aneja S, Kohli K. Add-on melatonin improves quality of life in epileptic children on valproate monotherapy: a randomized, double-blind, placebo-controlled trial. Epilepsy Behav 2004; 5(3):316–321.PubMedCrossRefGoogle Scholar
  16. 16.
    van der Heijden KB, Smits MG, Gunning WB. Sleep hygiene and actigraphically evaluated sleep characteristics in children with ADHD and chronic sleep onset insomnia. J Sleep Res 2006; 15(1):55–62.PubMedCrossRefGoogle Scholar
  17. 17.
    van der Heijden KB, Smits MG, van Someren EJ, Gunning WB. Idiopathic chronic sleep onset insomnia in attention-deficit/hyperactivity disorder: a circadian rhythm sleep disorder. Chronobiol Int 2005; 22(3):559–570.PubMedCrossRefGoogle Scholar
  18. 18.
    van der Heijden KB, Smits MG, Gunning WB. Sleep-related disorders in ADHD: a review. Clin Pediatr (Phila) 2005; 44(3):201–210.CrossRefGoogle Scholar
  19. 19.
    Lundmark PO, Pandi-Perumal SR, Srinivasan V, Cardinali DP. Role of melatonin in the eye and ocular dysfunctions. Vis Neurosci 2006; 23(6):853–862.PubMedCrossRefGoogle Scholar
  20. 20.
    Bubenik GA. Gastrointestinal melatonin: localization, function, and clinical relevance. Dig Dis Sci 2002; 47(10): 2336–2348.PubMedCrossRefGoogle Scholar
  21. 21.
    Carrillo-Vico A, Calvo JR, Abreu P, Lardone PJ, Garcia-Maurino S, Reiter RJ et al. Evidence of melatonin synthesis by human lymphocytes and its physiological significance: possible role as intracrine, autocrine, and/or paracrine substance. FASEB J 2004; 18(3):537–539.PubMedGoogle Scholar
  22. 22.
    Slominski A, Wortsman J, Tobin DJ. The cutaneous serotoninergic/melatoninergic system: securing a place under the sun. FASEB J 2005; 19(2):176–194.PubMedCrossRefGoogle Scholar
  23. 23.
    Axelrod J. The pineal gland: a neurochemical transducer. Science 1974; 184(144):1341–1348.PubMedCrossRefGoogle Scholar
  24. 24.
    Morin LP, Allen CN. The circadian visual system, 2005. Brain Res Rev 2006; 51(1):1–60.PubMedCrossRefGoogle Scholar
  25. 25.
    Berson DM, Dunn FA, Takao M. Phototransduction by retinal ganglion cells that set the circadian clock. Science 2002; 295(5557):1070–1073.PubMedCrossRefGoogle Scholar
  26. 26.
    Kennaway DJ, Stamp GE, Goble FC. Development of melatonin production in infants and the impact of prematurity. J Clin Endocrinol Metab 1992; 75(2):367–369.PubMedCrossRefGoogle Scholar
  27. 27.
    Arendt J. Melatonin and human rhythms. Chronobiol Int 2006; 23(1–2):21–37.PubMedCrossRefGoogle Scholar
  28. 28.
    Reiter RJ. Melatonin, active oxygen species and neurological damage. Drug News Perspect 1998; 11(5):291–296.PubMedCrossRefGoogle Scholar
  29. 29.
    Hardeland R. Antioxidative protection by melatonin: multiplicity of mechanisms from radical detoxification to radical avoidance. Endocrine 2005; 27(2):119–130.PubMedCrossRefGoogle Scholar
  30. 30.
    Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med Rev 2005; 9(1):11–24.PubMedCrossRefGoogle Scholar
  31. 31.
    Lavie P. Melatonin: role in gating nocturnal rise in sleep propensity. J Biol Rhythms 1997; 12(6):657–665.PubMedCrossRefGoogle Scholar
  32. 32.
    Zisapel N. Circadian rhythm sleep disorders: pathophysiology and potential approaches to management. CNS Drugs 2001; 15(4):311–328.PubMedCrossRefGoogle Scholar
  33. 33.
    Brzezinski A, Vangel MG, Wurtman RJ, Norrie G, Zhdanova I, Ben Shushan A et al. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev 2005; 9(1):41–50.PubMedCrossRefGoogle Scholar
  34. 34.
    Scheer FA. Potential use of melatonin as adjunct antihypertensive therapy. Am J Hypertens 2005; 18(12 Pt 1):1619–1620.PubMedCrossRefGoogle Scholar
  35. 35.
    Cagnacci A, Cannoletta M, Renzi A, Baldassari F, Arangino S, Volpe A. Prolonged melatonin administration decreases nocturnal blood pressure in women. Am J Hypertens 2005; 18(12 Pt 1):1614–1618.PubMedCrossRefGoogle Scholar
  36. 36.
    Guerrero JM, Reiter RJ. Melatonin-immune system relationships. Curr Top Med Chem 2002; 2(2):167–179.PubMedCrossRefGoogle Scholar
  37. 37.
    Esquifino AI, Pandi-Perumal SR, Cardinali DP. Circadian organization of the immune response: a role for melatonin . Clin Appl Immunol Rev 2004; 4:423–433.CrossRefGoogle Scholar
  38. 38.
    Srinivasan V, Maestroni GJM, Cardinali DP, Esquifino AI, Pandi-Perumal SR, Miller SC. Melatonin, immune function and aging. Immun Ageing 2005; 2:17.PubMedCrossRefGoogle Scholar
  39. 39.
    Armstrong SM. Melatonin and circadian control in mammals. Experientia 1989; 45(10):932–938.PubMedCrossRefGoogle Scholar
  40. 40.
    Iuvone PM, Tosini G, Pozdeyev N, Haque R, Klein DC, Chaurasia SS. Circadian clocks, clock networks, arylalkylamine N-acetyltransferase, and melatonin in the retina. Prog Retin Eye Res 2005; 24(4):433–456.PubMedCrossRefGoogle Scholar
  41. 41.
    Reiter RJ, Tan DX, Maldonado MD. Melatonin as an antioxidant: physiology versus pharmacology. J Pineal Res 2005; 39(2):215–216.PubMedCrossRefGoogle Scholar
  42. 42.
    Blask DE, Dauchy RT, Sauer LA. Putting cancer to sleep at night: the neuroendocrine/circadian melatonin signal. Endocrine 2005; 27(2):179–188.PubMedCrossRefGoogle Scholar
  43. 43.
    Miller SC, Pandi-Perumal SR, Esquifino AI, Cardinali DP, Maestroni GJ. The role of melatonin in immuno-enhancement: potential application in cancer. Int J Exp Pathol 2006; 87(2): 81–87.Google Scholar
  44. 44.
    Cardinali DP, Ladizesky MG, Boggio V, Cutrera RA, Mautalen C. Melatonin effects on bone: experimental facts and clinical perspectives. J Pineal Res 2003; 34(2): 81–87.PubMedCrossRefGoogle Scholar
  45. 45.
    Dubocovich ML, Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine 2005; 27(2): 101–110.PubMedCrossRefGoogle Scholar
  46. 46.
    Carlberg C. Gene regulation by melatonin. Ann N Y Acad Sci 2000; 917:387–396.PubMedCrossRefGoogle Scholar
  47. 47.
    Benitez-King G. Melatonin as a cytoskeletal modulator: implications for cell physiology and disease. J Pineal Res 2006; 40(1):1–9.PubMedCrossRefGoogle Scholar
  48. 48.
    Mailliet F, Ferry G, Vella F, Thiam K, Delagrange P, Boutin JA. Organs from mice deleted for NRH:quinone oxidoreductase 2 are deprived of the melatonin binding site MT3. FEBS Lett 2004; 578(1–2):116–120.PubMedCrossRefGoogle Scholar
  49. 49.
    Cardinali DP, Golombek DA, Rosenstein RE, Cutrera RA, Esquifino AI. Melatonin site and mechanism of action: single or multiple? J Pineal Res 1997; 23(1):32–39.PubMedCrossRefGoogle Scholar
  50. 50.
    Pandi-Perumal SR, Srinivasan V, Maestroni GJM, Cardinali DP, Poeggeler B, Hardeland R. Melatonin: nature’s most versatile biological signal? FEBS J 2006; 273:2813–2838.PubMedCrossRefGoogle Scholar
  51. 51.
    Nosjean O, Ferro M, Coge F, Beauverger P, Henlin JM, Lefoulon F et al. Identification of the melatonin-binding site MT3 as the quinone reductase 2. J Biol Chem 2000; 275(40):31311–31317.PubMedCrossRefGoogle Scholar
  52. 52.
    Foster CE, Bianchet MA, Talalay P, Faig M, Amzel LM. Structures of mammalian cytosolic quinone reductases. Free Radic Biol Med 2000; 29(3–4):241–245.PubMedCrossRefGoogle Scholar
  53. 53.
    Andrabi SA, Sayeed I, Siemen D, Wolf G, Horn TF. Direct inhibition of the mitochondrial permeability transition pore: a possible mechanism responsible for anti-apoptotic effects of melatonin. FASEB J 2004; 18(7):869–871.PubMedGoogle Scholar
  54. 54.
    Costa e Silva JA. Sleep disorders in psychiatry. Metabolism 2006; 55(10 Suppl 2):S40–S44.PubMedCrossRefGoogle Scholar
  55. 55.
    Maggi S, Langlois JA, Minicuci N, Grigoletto F, Pavan M, Foley DJ et al. Sleep complaints in community-dwelling older persons: prevalence, associated factors, and reported causes. J Am Geriatr Soc 1998; 46:161–168.PubMedGoogle Scholar
  56. 56.
    Pandi-Perumal SR, Seils LK, Kayumov L, Ralph MR, Lowe A, Moller H et al. Senescence, sleep, and circadian rhythms. Ageing Res Rev 2002; 1(3):559–604.PubMedCrossRefGoogle Scholar
  57. 57.
    Leger D, Laudon M, Zisapel N. Nocturnal 6-sulfatoxymelatonin excretion in insomnia and its relation to the response to melatonin replacement therapy. Am J Med 2004; 116(2):91–95.PubMedCrossRefGoogle Scholar
  58. 58.
    Kripke DF, Jean-Louis G, Elliott JA, Klauber MR, Rex KM, Tuunainen A et al. Ethnicity, sleep, mood, and illumination in postmenopausal women. BMC Psychiatry 2004; 4(1):8.PubMedCrossRefGoogle Scholar
  59. 59.
    Tuunainen A, Kripke DF, Elliott JA, Assmus JD, Rex KM, Klauber MR et al. Depression and endogenous melatonin in postmenopausal women. J Affect Disord 2002; 69(1–3): 149–158.PubMedCrossRefGoogle Scholar
  60. 60.
    Tozawa T, Mishima K, Satoh K, Echizenya M, Shimizu T, Hishikawa Y. Stability of sleep timing against the melatonin secretion rhythm with advancing age: clinical implications. J Clin Endocrinol Metab 2003; 88(10): 4689–4695.PubMedCrossRefGoogle Scholar
  61. 61.
    Siegrist C, Benedetti C, Orlando A, Beltran JM, Tuchscherr L, Noseda CM et al. Lack of changes in serum prolactin, FSH, TSH, and estradiol after melatonin treatment in doses that improve sleep and reduce benzodiazepine consumption in sleep-disturbed, middle-aged, and elderly patients. J Pineal Res 2001; 30(1):34–42.PubMedCrossRefGoogle Scholar
  62. 62.
    Bellipanni G, DI Marzo F, Blasi F, Di Marzo A. Effects of melatonin in perimenopausal and menopausal women: our personal experience. Ann N Y Acad Sci 2005; 1057:393–402.PubMedCrossRefGoogle Scholar
  63. 63.
    Zisapel N. The use of melatonin for the treatment of insomnia. Biol Signals Recept 1999; 8(1–2):84–89.PubMedCrossRefGoogle Scholar
  64. 64.
    Monti JM, Cardinali DP. A critical assessment of the melatonin effect on sleep in humans. Biol Signals Recept 2000; 9(6):328–339.PubMedCrossRefGoogle Scholar
  65. 65.
    Zhdanova IV, Wurtman RJ, Regan MM, Taylor JA, Shi JP, Leclair OU. Melatonin treatment for age-related insomnia. J Clin Endocrinol Metab 2001; 86(10):4727–4730.PubMedCrossRefGoogle Scholar
  66. 66.
    Weiss MD, Wasdell MB, Bomben MM, Rea KJ, Freeman RD. Sleep hygiene and melatonin treatment for children and adolescents with ADHD and initial insomnia. J Am Acad Child Adolesc Psychiatry 2006; 45(5):512–519.PubMedCrossRefGoogle Scholar
  67. 67.
    Tjon Pian Gi CV, Broeren JP, Starreveld JS, Versteegh FG. Melatonin for treatment of sleeping disorders in children with attention deficit/hyperactivity disorder: a preliminary open label study. Eur J Pediatr 2003; 162(7–8):554–555.PubMedCrossRefGoogle Scholar
  68. 68.
    van der Heijden KB, Smits M, van Someren EJ, Ridderinkhof KR, Gunning WB. Effect of melatonin on sleep, problem behaviour, cognitive performance, and quality of life in children with attention/deficit–hyperactivity disorder and chronic sleep onset insomnia. J Am Acad Child Adolesc Psychiatry 2007; 46(2):233–241.PubMedCrossRefGoogle Scholar
  69. 69.
    Regestein QR, Monk TH. Delayed sleep phase syndrome: a review of its clinical aspects. Am J Psychiatry 1995; 152(4):602–608.PubMedGoogle Scholar
  70. 70.
    Weitzman ED, Czeisler CA, Coleman RM, Spielman AJ, Zimmerman JC, Dement W et al. Delayed sleep phase syndrome. A chronobiological disorder with sleep-onset insomnia. Arch Gen Psychiatry 1981; 38(7):737–746.PubMedGoogle Scholar
  71. 71.
    Nagtegaal JE, Laurant MW, Kerkhof GA, Smits MG, van der Meer YG, Coenen AM. Effects of melatonin on the quality of life in patients with delayed sleep phase syndrome. J Psychosom Res 2000; 48(1):45–50.PubMedCrossRefGoogle Scholar
  72. 72.
    Tarlov AR, Ware JE, Jr., Greenfield S, Nelson EC, Perrin E, Zubkoff M. The Medical Outcomes Study. An application of methods for monitoring the results of medical care. JAMA 1989; 262(7):925–930.PubMedCrossRefGoogle Scholar
  73. 73.
    Smith IE, Shneerson JM. Is the SF 36 sensitive to sleep disruption? A study in subjects with sleep apnoea. J Sleep Res 1995; 4(3):183–188.PubMedGoogle Scholar
  74. 74.
    Dahlitz M, Alvarez B, Vignau J, English J, Arendt J, Parkes JD. Delayed sleep phase syndrome response to melatonin. Lancet 1991; 337(8750):1121–1124.PubMedCrossRefGoogle Scholar
  75. 75.
    Srinivasan V, Smits G, Kayumov L, Pandi-Perumal SR, Cardinali DP, Thorpy MJ. Melatonin in circadian rhythm sleep disorders. In: Cardinali DP, Pandi-Perumal SR, editors. Neuroendocrine Correlates of Sleep/Wakefulness. New York: Springer, 2006:269–294.Google Scholar
  76. 76.
    Citera G, Arias MA, Maldonado-Cocco JA, Lazaro MA, Rosemffet MG, Brusco LI et al. The effect of melatonin in patients with fibromyalgia: a pilot study. Clin Rheumatol 2000; 19(1):9–13.PubMedCrossRefGoogle Scholar
  77. 77.
    Acuña-Castroviejo D, Escames G, Reiter RJ. Melatonin therapy in fibromyalgia. J Pineal Res 2006; 40(1):98–99.PubMedCrossRefGoogle Scholar
  78. 78.
    Cardinali DP, Ritta MN, Fuentes AM, Gimeno MF, Gimeno AL. Prostaglandin E release by rat medial basal hypothalamus in vitro. Inhibition by melatonin at submicromolar concentrations. Eur J Pharmacol 1980; 67:151–153.PubMedCrossRefGoogle Scholar
  79. 79.
    van Heukelom RO, Prins JB, Smits MG, Bleijenberg G. Influence of melatonin on fatigue severity in patients with chronic fatigue syndrome and late melatonin secretion. Eur J Neurol 2006; 13(1):55–60.PubMedCrossRefGoogle Scholar
  80. 80.
    Pearce JM. A critical appraisal of the chronic whiplash syndrome. J Neurol Neurosurg Psychiatry 1999; 66(3): 273–276.PubMedCrossRefGoogle Scholar
  81. 81.
    Wieringer Sv, Jansen T, Smits MG, Nagtegaal JE, Coenen AML. Melatonin for chronic whiplash syndrome with delayed melatonin onset. Randomised, placebo-controlled trial. Clin Drug Invest 2001; 21:813–820.CrossRefGoogle Scholar
  82. 82.
    Revell VL, Eastman CI. How to trick mother nature into letting you fly around or stay up all night. J Biol Rhythms 2005; 20(4):353–365.PubMedCrossRefGoogle Scholar
  83. 83.
    Arendt J, Skene DJ. Melatonin as a chronobiotic. Sleep Med Rev 2005; 9(1):25–39.PubMedCrossRefGoogle Scholar
  84. 84.
    Takahashi T, Sasaki M, Itoh H, Yamadera W, Ozone M, Obuchi K et al. Melatonin alleviates jet lag symptoms caused by an 11-hour eastward flight. Psychiatry Clin Neurosci 2002; 56(3):301–302.PubMedCrossRefGoogle Scholar
  85. 85.
    Herxheimer A. Jet lag. Clin Evid 2005;(13):2178–2183.PubMedGoogle Scholar
  86. 86.
    Cardinali DP, Bortman GP, Liotta G, Perez LS, Albornoz LE, Cutrera RA et al. A multifactorial approach employing melatonin to accelerate resynchronization of sleep-wake cycle after a 12 time-zone westerly transmeridian flight in elite soccer athletes. J Pineal Res 2002; 32(1):41–46.PubMedCrossRefGoogle Scholar
  87. 87.
    Costa G. Flexibility of working hours in the 24-hour society. Med Lav 2006; 97(2):280–287.PubMedGoogle Scholar
  88. 88.
    Knutsson A, Boggild H. Shiftwork and cardiovascular disease: review of disease mechanisms. Rev Environ Health 2000; 15(4):359–372.PubMedGoogle Scholar
  89. 89.
    Akerstedt T, Knutsson A, Westerholm P, Theorell T, Alfredsson L, Kecklund G. Mental fatigue, work and sleep. J Psychosom Res 2004; 57(5):427–433.PubMedCrossRefGoogle Scholar
  90. 90.
    Schernhammer ES, Kroenke CH, Laden F, Hankinson SE. Night work and risk of breast cancer. Epidemiology 2006; 17(1):108–111.PubMedCrossRefGoogle Scholar
  91. 91.
    Quera-Salva MA, Guilleminault C, Claustrat B, Defrance R, Gajdos P, McCann CC et al. Rapid shift in peak melatonin secretion associated with improved performance in short shift work schedule. Sleep 1997; 20(12):1145–1150.PubMedGoogle Scholar
  92. 92.
    Folkard S, Arendt J, Clark M. Can melatonin improve shift workers’ tolerance of the night shift? Some preliminary findings. Chronobiol Int 1993; 10(5):315–320.PubMedCrossRefGoogle Scholar
  93. 93.
    Burgess HJ, Sharkey KM, Eastman CI. Bright light, dark and melatonin can promote circadian adaptation in night shift workers. Sleep Med Rev 2002; 6(5):407–420.PubMedGoogle Scholar
  94. 94.
    Cavallo A, Ris MD, Succop P, Jaskiewicz J. Melatonin treatment of pediatric residents for adaptation to night shift work. Ambul Pediatr 2005; 5(3):172–177.PubMedCrossRefGoogle Scholar
  95. 95.
    McCurry SM, Reynolds CF, Ancoli-Israel S, Teri L, Vitiello MV. Treatment of sleep disturbance in Alzheimer’s disease. Sleep Med Rev 2000; 4(6):603–628.PubMedCrossRefGoogle Scholar
  96. 96.
    Mishima K, Tozawa T, Satoh K, Matsumoto Y, Hishikawa Y, Okawa M. Melatonin secretion rhythm disorders in patients with senile dementia of Alzheimer’s type with disturbed sleep-waking. Biol Psychiatry 1999; 45(4):417–421.PubMedCrossRefGoogle Scholar
  97. 97.
    Mishima K, Okawa M, Hozumi S, Hishikawa Y. Supplementary administration of artificial bright light and melatonin as potent treatment for disorganized circadian rest-activity and dysfunctional autonomic and neuroendocrine systems in institutionalized demented elderly persons. Chronobiol Int 2000; 17(3):419–432.PubMedCrossRefGoogle Scholar
  98. 98.
    Zhou JN, Liu RY, Kamphorst W, Hofman MA, Swaab DF. Early neuropathological Alzheimer’s changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. J Pineal Res 2003; 35(2):125–130.PubMedCrossRefGoogle Scholar
  99. 99.
    Taylor JL, Friedman L, Sheikh J, Yesavage JA. Assessment and management of “sundowning” phenomena. Semin Clin Neuropsychiatry 1997; 2:113–122.PubMedGoogle Scholar
  100. 100.
    Fainstein I, Bonetto A, Brusco LI, Cardinali DP. Effects of melatonin in elderly patients with sleep disturbance. A pilot study. Curr Ther Res 1997; 58:990–1000.CrossRefGoogle Scholar
  101. 101.
    Jean-Louis G, von Gizycki H, Zizi F. Melatonin effects on sleep, mood, and cognition in elderly with mild cognitive impairment. J Pineal Res 1998; 25(3):177–183.PubMedCrossRefGoogle Scholar
  102. 102.
    Cohen-Mansfield J, Garfinkel D, Lipson S. Melatonin for treatment of sundowning in elderly persons with dementia – a preliminary study. Arch Gerontol Geriatr 2000; 31(1): 65–76.PubMedCrossRefGoogle Scholar
  103. 103.
    Mahlberg R, Kunz D, Sutej I, Kuhl KP, Hellweg R. Melatonin treatment of day-night rhythm disturbances and sundowning in Alzheimer disease: an open-label pilot study using actigraphy. J Clin Psychopharmacol 2004; 24(4):456–459.PubMedCrossRefGoogle Scholar
  104. 104.
    Brusco LI, Marquez M, Cardinali DP. Melatonin treatment stabilizes chronobiologic and cognitive symptoms in Alzheimer’s disease. Neuro Endocrinology Lett 1998; 19:111–115.Google Scholar
  105. 105.
    Cardinali DP, Brusco LI, Liberczuk C, Furio AM. The use of melatonin in Alzheimer’s disease. Neuro Endocrinol Lett 2002; 23(Suppl 1):20–23.PubMedGoogle Scholar
  106. 106.
    Asayama K, Yamadera H, Ito T, Suzuki H, Kudo Y, Endo S. Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia. J Nippon Med Sch 2003; 70(4):334–341.PubMedCrossRefGoogle Scholar
  107. 107.
    Singer C, Tractenberg RE, Kaye J, Schafer K, Gamst A, Grundman M et al. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer’s disease. Sleep 2003; 26(7):893–901.PubMedGoogle Scholar
  108. 108.
    Srinivasan V, Smits M, Spence W, Lowe AD, Kayumov L, Pandi-Perumal SR et al. Melatonin in mood disorders. World J Biol Psychiatry 2006; 7(3):138–151.PubMedCrossRefGoogle Scholar
  109. 109.
    Wehr TA. Sleep-loss as a possible mediator of diverse causes of mania. Br J Psychiatry 1991; 159:576–578.PubMedGoogle Scholar
  110. 110.
    Riemann D, Berger M, Voderholzer U. Sleep and depression–results from psychobiological studies: an overview. Biol Psychol 2001; 57(1–3):67–103.PubMedCrossRefGoogle Scholar
  111. 111.
    Rosenthal NE, Sack DA, Gillin JC, Lewy AJ, Goodwin FK, Davenport Y et al. Seasonal affective disorder. A description of the syndrome and preliminary findings with light therapy. Arch Gen Psychiatry 1984; 41(1):72–80.PubMedGoogle Scholar
  112. 112.
    Lewy AJ, Sack RL, Singer CM, White DM. The phase shift hypothesis for bright light’s therapeutic mechanism of action: theoretical considerations and experimental evidence. Psychopharmacol Bull 1987; 23(3):349–353.PubMedGoogle Scholar
  113. 113.
    Terman M, Quitkin FM, Terman JS, Stewart JW, McGrath PJ. The timing of phototherapy: effects on clinical response and the melatonin cycle. Psychopharmacol Bull 1987; 23(3):354–357.PubMedGoogle Scholar
  114. 114.
    Wehr TA, Duncan WC, Jr., Sher L, Aeschbach D, Schwartz PJ, Turner EH et al. A circadian signal of change of season in patients with seasonal affective disorder. Arch Gen Psychiatry 2001; 58(12):1108–1114.PubMedCrossRefGoogle Scholar
  115. 115.
    Leppamaki S, Partonen T, Vakkuri O, Lonnqvist J, Partinen M, Laudon M. Effect of controlled-release melatonin on sleep quality, mood, and quality of life in subjects with seasonal or weather-associated changes in mood and behaviour. Eur Neuropsychopharmacol 2003; 13(3):137–145.PubMedCrossRefGoogle Scholar
  116. 116.
    Solberg EE, Halvorsen R, Sundgot-Borgen J, Ingjer F, Holen A. Meditation: a modulator of the immune response to physical stress? A brief report. Br J Sports Med 1995; 29(4):255–257.PubMedGoogle Scholar
  117. 117.
    Massion AO, Teas J, Hebert JR, Wertheimer MD, Kabat-Zinn J. Meditation, melatonin and breast/prostate cancer: hypothesis and preliminary data. Med Hypotheses 1995; 44(1):39–46.PubMedCrossRefGoogle Scholar
  118. 118.
    Tooley GA, Armstrong SM, Norman TR, Sali A. Acute increases in night-time plasma melatonin levels following a period of meditation. Biol Psychol 2000; 53(1):69–78.PubMedCrossRefGoogle Scholar
  119. 119.
    Harinath K, Malhotra AS, Pal K, Prasad R, Kumar R, Kain TC et al. Effects of Hatha yoga and Omkar meditation on cardiorespiratory performance, psychologic profile, and melatonin secretion. J Altern Complement Med 2004; 10(2):261–268.PubMedCrossRefGoogle Scholar
  120. 120.
    Carlson LE, Speca M, Patel KD, Goodey E. Mindfulness-based stress reduction in relation to quality of life, mood, symptoms of stress and levels of cortisol, dehydroepiandrosterone sulfate (DHEAS) and melatonin in breast and prostate cancer outpatients. Psychoneuroendocrinology 2004; 29(4):448–474.PubMedCrossRefGoogle Scholar
  121. 121.
    Cos S, Gonzalez A, Martinez-Campa C, Mediavilla MD, Alonso-Gonzalez C, Sanchez-Barcelo EJ. Estrogen-signaling pathway: a link between breast cancer and melatonin oncostatic actions. Cancer Detect Prev 2006; 30(2):118–128.PubMedCrossRefGoogle Scholar
  122. 122.
    Kiefer T, Ram PT, Yuan L, Hill SM. Melatonin inhibits estrogen receptor transactivation and cAMP levels in breast cancer cells. Breast Cancer Res Treat 2002; 71(1):37–45.PubMedCrossRefGoogle Scholar
  123. 123.
    Song GH, Leng PH, Gwee KA, Moochhala SM, Ho KY. Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: a randomised, double blind, placebo controlled study. Gut 2005; 54(10):1402–1407.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press, Totowa, NJ 2008

Authors and Affiliations

  • Venkataramanujan Srinivasan
  • S. R. Pandi-Perumal
  • Warren Spence
  • Daniel P. Cardinali
  • Marcel G. Smits

There are no affiliations available

Personalised recommendations